Search results
Results from the WOW.Com Content Network
The PFA-100 (Platelet Function Assay [1] or Platelet Function Analyser [2]) is a platelet function analyser that aspirates blood in vitro from a blood specimen into disposable test cartridges through a microscopic aperture cut into a biologically active membrane at the end of a capillary.
Multiplate multiple electrode aggregometry (MEA) is a test of platelet function in whole blood. [1] [2] The test can be used to diagnose platelet disorders, [3] [4] [5] monitor antiplatelet therapy, [6] and is also investigated as a potential predictor of transfusion requirements and bleeding risk in cardiac surgery. [7]
Bleeding time is a medical test done to assess the function of a person's platelets. It involves making a patient bleed, then timing how long it takes for them to stop bleeding using a stopwatch or other suitable devices. The term template bleeding time is used when the test is performed to standardized parameters.
The PFA-100 (Platelet Function Assay — 100) is a system for analysing platelet function in which citrated whole blood is aspirated through a disposable cartridge containing an aperture within a membrane coated with either collagen and epinephrine or collagen and ADP. These agonists induce platelet adhesion, activation and aggregation, leading ...
The ristocetin-induced platelet aggregation (RIPA) is an ex vivo assay for live platelet function. It measures platelet aggregation with the help of von Willebrand factor (vWF) and exogenous antibiotic ristocetin added in a graded fashion. [ 1 ]
Hematology analyzers (also spelled haematology analysers in British English) are used to count and identify blood cells at high speed with accuracy. [1] [2] [3] During the 1950s, laboratory technicians counted each individual blood cell underneath a microscope.
Tests in platelet rich plasma (close to real conditions in the body, but restrictions as to the terms of work), Tests in whole blood (the most adjusted to human physiology; the test can be started immediately; but the least convenient due to terms of blood storage and difficulties of the results' interpretation).
Following a 60-mg loading dose of the drug, about 90% of patients had at least 50% inhibition of platelet aggregation by one hour. Maximum platelet inhibition was about 80%. Mean steady-state inhibition of platelet aggregation was about 70% following three to five days of dosing at 10 mg daily after a 60-mg loading dose.